SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r/m Nasopharyngeal Carcinoma - Trial NCT06323239
Access comprehensive clinical trial information for NCT06323239 through Pure Global AI's free database. This Phase 2 trial is sponsored by Sun Yat-sen University and is currently Not yet recruiting. The study focuses on Nasopharyngeal Carcinoma. Target enrollment is 148 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Sun Yat-sen University
Timeline & Enrollment
Phase 2
Apr 01, 2024
Apr 01, 2028
Primary Outcome
Progression-free survival
Summary
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to
 evaluate the efficacy and adverse effect of SBRT and LDRT combined with programmed death 1
 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06323239
Non-Device Trial